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Interstitial inflammation and fibrosis in rats with diet-induced
hypercholesterolemia
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Interstitial inflammation and fibrosis in rats with diet-induced hyper-
cholesterolemia. Abnormalities in lipid metabolism appear to play a
pathogenic role in progressive renal disease. To elucidate the cellular and
molecular basis of renal interstitial fibrosis in uninephrectomized rats with
diet-induced hypercholesterolemia, we fed experimental rats with stan-
dard rat chow supplemented with 4% cholesterol and 1% cholic acid.
Control rats were fed an isocalorie diet. Groups of 7 control and 7
experimental rats were killed after 4, 8, and 12 weeks. Hypercholester-
olemic rats developed albuminuria; serum creatinine was elevated at 12
weeks. By 12 weeks numerous oil red 0-positive cells were present
throughout the interstitium and to a lesser extent in tubules. Total renal
lipid-peroxidation products were significantly increased (172 15, 198
28, and 197 13 mmol malondialdehyde/kidney at 4, 8, and 12 weeks vs.
123 17, 144 6, and 125 10 mmol in controls). Immunostaining
revealed oxidatively modified lipoproteins within tubular and interstitial
cells. The interstitial disease was characterized by an interstitial infiltrate
of monocytes. Significant increases were detected in renal cortical mRNA
levels for monocyte chemoattractant protein-i (MCP-i), osteopontin, and
vascular cell adhesion molecule-i (VCAM-1), associated with changes in
the pattern of immunostaining for each encoded proteins. Total kidney
collagen was significantly increased at 12 weeks (9.8 0.9 mg/kidney vs.
7.8 0.9 mg in controls). At 12 weeks there was a significant increase in
interstitial immunostaining for collagen I, collagen III, collagen IV,
fibronectin and tenascin. A significant threefold increase in renal cortical
mRNA levels for transforming growth factor beta-i (TGF-i) at 4 and 12
weeks was associated with the appearance of TGF-i-positive interstitial
cells. Renal matrix protein mRNA levels were measured at 4, 8, and 12
weeks. The only statistically significant elevations were procollagen nl(I)
and procollagen al(III) at weeks 8 and 12. In contrast, renal cortical
mRNA levels for the tissue inhibitor of metalloproteinases-i (TIMP-1)
were significantly increased at 4, 8 and 12 weeks (1.4 0.5, 2.7 0.9 and
2.7 1.4 arbitrary densitometric units, respectively, vs. 1.0 0.4, 1.0 0.5
and 1.0 0.4 units for controls), and urokinase-type plasminogen
activator (pYA) mRNA levels were significantly decreased at 4, 8, and 12
weeks (0.4 0.1 arbitrary densitometrie units for all three experimental
groups vs. 1.0 0.4, 1.0 0.3, and 1.0 0.4units for the control groups).
In summary, rats with diet-induced hypereholesterolemia develop renal
interstitial fibrosis over several weeks. Following the accumulation of
lipids within tubulointerstitial cells, interstitial nephritis develops. The
fibrotic phase is characterized by modest changes in matrix protein mRNA
levels, up-regulated TIMP-1, and down-regulated pPA levels, suggesting
that altered matrix degradation plays a role in the interstitial fihrogenesis
in this model.
Abnormalities in lipid metabolism appear to play a pathogenic
role in progressive renal disease. Supportive evidence dates all the
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way back to Virchow's 1860 report of fatty degeneration in the
kidneys of patients with Bright's disease [1]. However, progress in
this field was relatively slow until 1982, when Moorhead and
colleagues suggested that lipoproteins produced by the liver in
response to proteinuria might contribute to progressive renal
disease [2]. Since that time, several studies based on animal
models have provided evidence that a pathogenetic relationship
exists between elevated plasma lipid levels and glomerular injury
[3—7]. For example, manipulations that alter serum lipids influ-
ence glomerular injury in rats with puromycin aminonucleoside
nephrosis [8, 9], ureteral obstruction [10], and 5/6 nephrectomy
[11, 121, and they influence the glomerular disease that develops
spontaneously in obese Zucker rats [13]. Furthermore, feeding
high-cholesterol diets to normal rats [14, 15], guinea pigs [16], and
rabbits [17] causes renal disease that is not present in animals fed
standard laboratory chow [14—17].
To date very little attention has been paid to the potential role
of hyperlipidemia as a cause of the tubulointerstitial damage that
typifies progressive renal injury, despite speculation by Moorhead
et a! that lipiduria may be an independent progression factor [2].
Wellmann and Volk [17] reported interstitial foam cells and foci
of interstitial fibrosis in rabbits with diet-induced hypereholester-
olemia. Peric-Golia and Perie-Golia [18] described interstitial
fibrosis in rats fed a high-cholesterol diet for 80 weeks. In both
normal and uninephrectomized rats, Kasiske et al reported sig-
nificant tubulointerstitial damage in the rats fed a diet high in
cholesterol for 19 weeks compared to rats fed standard chow [151.
This group also reported the presence of significant tubulointer-
stitial injury in obese Zucker rats with endogenous hypercholes-
terolemia 32 weeks after uninephrectomy [19]. In both of these rat
studies, the investigators found a significant positive correlation
between the content of esterified cholesterol in the renal cortex
and the severity of the tubulointerstitial damage. Modi et al
reported an attenuation of tubulointerstitial disease associated
with a significant reduction in serum cholesterol levels in rats that
were treated with probueol after subtotal nephrectomy [12].
ApoB, the major human low-density lipoprotein (LDL) apopro-
tein, has been shown to accumulate in the interstitium and in
tubular cells in patients with nephrotie syndrome [20].
The pathogenetic basis of the relationship between hyper-
lipidemia and renal injury remains unclear, although certain
morphologic parallels with atherosclerosis suggest that common
mechanisms of tissue injury may exist. In particular, oxidized
lipoproteins (oxLDL) and cells of the monocyte-macrophage
lineage appear to play a critical role [21—23]. Oxidized LDL has
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monocyte chemotactic activity [241. Exposure of endothelial cells
to oxidized LDL may also enhance monocyte-endothelial inter-
actions by upregulating the expression of adhesion molecules such
as the 2 integrins [25, 26], intercellular adhesion molecule-I
(ICAM-l), and vascular cell adhesion molecule-I (VCAM-1) [27,
281, and by increasing the synthesis of monocyte chemotactic
factors [29]. Macrophages express scavenger receptors that pro-
cess oxidized [30] but not native LDL. Although tubular cells can
internalize oxidized LDL [31, 32], the specific receptors involved
have not yet been identified. Two scavenger receptors for oxidized
LDL have recently been cloned from several animal species
[33—36], and they appear to be products of a single gene [371. In
the current model of atherogenesis, it has been proposed that the
uptake of oxidized LDL by macrophage scavenger receptors
stimulates the synthesis of growth factors, cytokines, and other
mediators of matrix-protein synthesis [38, 39].
The present study was designed to elucidate the cellular and
molecular basis of renal interstitial fibrosis in uninephrectomized
rats with diet-induced hypercholesterolemia. Our results show
that tubulointerstitial disease develops slowly. The earliest mor-
phologic change is the detection of lipid deposits within interstitial
cells. At 4 weeks renal cortical osteopontin mRNA levels are
significantly increased, and remain elevated at 8 and 12 weeks. By
8 weeks there is a significant increase in renal monocyte chemoat-
tractant protein-I mRNA levels and the number of interstitial
macrophages. At 12 weeks the kidney collagen content and
interstitial immunostaining for several matrix proteins are in-
creased. The results of a serial evaluation of renal mRNA levels
suggest that increased expression of transforming growth factor
beta-i (TGF-i) and the tissue inhibitor of metalloproteinases-l
(TIMP-I) and decreased expression of urokinase-type plasmino-
gen activator (SPA) may contribute to interstitial fibrosis in this
model.
Methods
Experimental design
Forty-two female Sprague-Dawley rats weighing 100 to 120 g
were purchased from Charles River Breeding Laboratories
(Wilmington, MA, USA). We performed a left nephrectomy on
each animal five days before the study began. Half of the animals
were fed standard rat chow (Purina Rodent Laboratoiy Chow
5001; Purina Mills Inc., Richmond, IN, USA) supplemented with
4% cholesterol and 1% cholic acid (Purina Test Diets). The
control group was fed the standard chow containing 270 mg
cholesterol per kilogram that was prepared by the same manufac-
turer. Groups of 7 control rats and 7 rats on the high-cholesterol
diet were killed at 4, 8, and 12 weeks.
Each rat was housed individually in a metabolic cage at 4, 8, and
12 weeks, and the spontaneously voided urine was collected over
a 24-hour period. Animals were killed by exsanguination under
general anaesthesia by inhalation of nitrous oxide, oxygen, and
enflurane. At the time of death, a blood sample was taken, and the
remaining kidney was decapsulated and carefully weighed (wet
weight). The kidney was divided in half longitudinally. The renal
cortex was carefully dissected from one-half of the first piece and
snap-frozen in liquid nitrogen for extraction of total RNA. The
remainder of the first half was divided into smaller pieces of
cortex that were snap-frozen in isopentane pre-cooled in liquid
nitrogen for subsequent immunostaining. All tissues were stored
at —70°C.
The second half was divided into two parts, and both were
carefully weighed. The first piece was frozen in liquid nitrogen for
total collagen measurement and the second for measurement of
lipid peroxidation products. Renal peroxidation products were
assessed using the thiobarbituric-acid assay to assess the renal
malondialdehyde content according to the methods of Ohkawa,
Ohishi and Yagi [40].
Biochemical studies
Urinary albumin concentrations were measured by radial im-
munodiffusion [41]. Plasma creatinine and total cholesterol levels
were measured using the Kodak Ektachem Clinical Chemistry
slide technique on individual samples of heparinized blood ob-
tained when the rats were exsanguinated.
Total kidney collagen was calculated as previously described
[42], based on measurements of the hydroxyproline in kidney
homogenates according to the technique of Kivirikko, Laitinen
and Prockop [43]. Collagen was assumed to contain 12.7%
hydroxyproline by weight. Final results, based on the wet wt of the
kidney, are expressed as milligrams of collagen per kidney.
Renal immunofluorescence studies
Interstitial and intraglomerular monocytes/macrophages ex-
pressing the cytoplasmic marker ED-i (Serotec, Oxford, UK)
were counted on acetone-fixed kidney cryosections 3 m thick,
using the dual fluorochrome labeling and enumeration technique
previously described [41, 44j.
We assessed the accumulation of extracellular matrix proteins
within the cortical interstitium semiquantitatively with fluores-
cence microscopy, using the technique previously described [45].
The primary antibodies used were: sheep anti-human collagen I;
goat anti-human collagen III; goat anti-human collagen IV
(Southern Biotechnology Associates, Birmingham, AL, USA);
rabbit anti-human tenascin (a gift from Dr. H. Erickson, Duke
University, NC, USA); and a murine monoclonal antibody to
human extracellular domain A (EDA+) fibronectin, an attenu-
atively spliced form of fibronectin (a gift from Dr. L. Zardi,
Instituto Nazionale perla Rererca sul Cancro, Italy).
Cryostat sections were stained with oil red 0 to evaluate the
renal accumulation of neutral lipids. Evidence of recent tubular
injury was evaluated by immunostaining (with murine monoclonal
anti-vimentin antibody; ESBE Laboratory Supplies, Markham,
ON, Canada) for vimentin, an intermediate filament that is
transiently expressed by regenerating tubules. Tissue sections
from each animal group were evaluated by indirect immunofluo-
rescence staining for the pattern of expression of alpha smooth-
muscle actin (anti-rat smooth-muscle actin; Sigma Chemical
Company, St. Louis, MO, USA); arachidonic acid-modified and
linoleic acid-modified LDL (murine monoclonal antibodies; a gift
from Dr. U. Steinbrecher, University of British Columbia, Van-
couver, BC, Canada) [46]; MCP-i (rabbit anti-rat MCP-1 anti-
serum; a gift from Dr. J.S. Warren, University of Michigan
Medical Center, Ann Arbor, MI, USA); osteopontin (goat anti-rat
smooth-muscle osteopontin; a gift from Dr. C.M. Giachelli,
University of Washington, Seattle, WA, USA); VCAM-l (anti-rat
VCAM-1 monoclonal antibody; a gift from Dr. P. Chisholm,
Biogcn, Cambridge, MA, USA); ICAM-i (anti-rat ICAM-l
monoclonal antibody; Cedarlane Laboratories Ltd., l-lornby, ON,
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Table 1. Renal functional parameters
Group Week 4 Week 8 Week 12
C 250 11 292 18 318 21
H 238 18 259 11 286 23U
C 0.1 0.1 0.1 0.1 0.3 0.2
H 8.1 8.6" 19.4 8.1" 57.2 32.0"
C 51±5 49±4 46±6
H 44 3 46 6 52 4"
C 10±6 4±2 7±3
H 13±7 12±6" 44±11'
C 0.7 0.4 0.5 0.5 1.3 1.0
H 2.8 lU 2.7 1.3" 10.5 3.0"
C 1184 30 1273 67 1246 54
H 1307 121 1434 103" 1786 184"
Results are means 1 SI); N 7/group. Abbreviations are: C, control
group; H, hypercholesterolemic group.
up < 0.05 compared to the corresponding control group, by Mann-
Whitney U test
Canada); TGF-31 [rabbit anti-TGF-f31 (anti-LC) antibody; a gift
from Dr. K. Flanders, National Institute of Health, Bethesda,
MD, USA]; TIMP (rabbit anti-bovine TIMP; a gift from Dr. Y.A.
De Clerck, Children's Hospital of Los Angeles, Los Angeles, CA,
USA); and 1sPA (rabbit anti-human sPA; American Diagnostica
Inc., Greenwich, CT, USA). Unreferenced antibodies are cited in
our previous publications [42, 45, 47, 481. The secondary antisera
for detecting polyclonal antibodies were fluorescein isothiocya-
nate (FITC)-conjugated goat anti-rabbit IgG and FITC-conju-
gated rabbit anti-goat IgG antisera (Chemicon International Inc.,
Temecula, CA, USA). The secondary antiserum for detecting
murine rnonoclonal antibodies was FITC-conjugated goat anti-
mouse IgG (Zymed Laboratories Inc., San Francisco, CA, USA).
The FTTC-conjugated antisera were absorbed with normal rat
plasma; lack of staining showed them to be nonreactive with
control kidney sections. Code numbers were used to blind the
investigator to the animal group as each investigation was per-
formed.
Gene expression
We isolated total renal cortical RNA according to the guani-
dinium isothiocyanate-cesium chloride method of Chirgwin et al
[49], separated it by electrophoresis in a 1% agarose-formalde-
hyde gel, transferred it to a nylon membrane, and probed it with
32P dCTP-labeled complementary DNA probes, as described
previously [47]. We obtained autoradiographs and quantified the
bands by laser densitometry. The density reading of each band on
the autoradioaudiograph was adjusted for any RNA-loading
inequality as previously described [47].
The eDNA probes used were: rat MCP-1 (a gift from Dr. T.
Yoshimura, National Cancer Institute, Bethesda, MD, USA); rat
osteopontin (a gift from Dr. C.M. Giachelli, University of Wash-
ington, Seattle, WA, USA); rat VCAM-1 (a gift from Dr. T.
Collins, Harvard Medical School, Boston, MA, USA); rat TGF-j31
(a gift from Dr. S.W. Qian, National Cancer Institute); rat
macrophage colony-stimulating factor (M-CSF, American Tissue
Culture Collection no. 63,057); rat tumor-necrosis factor alpha
(TNF-a, a gift from Dr. W. Fiers, Roche Research, Gent,
Belgium); rat interleukin-1 beta (TL-lp, a gift from Dr. T. Nishida,
Otsuka Pharmaceutical Company Ltd., Japan) [50]; rat platelet-
derived growth factor A (PDGF-A, a gift from Dr. D. Mercola,
Parameter Group Week 4 Week 8 Week 12
Plasma cholesterol mmol/liter"
Renal peroxidation products
mmol malondialdehye
per kidney
C
H
C
H
1.3 0.1
5.1 1.5
123 17
172 15
1.4 0.1
4.3 1.1
144 6
198 28
1.3
3.1
125
197
0
1.0
10
13
Results are means 1 so; N = 7/group. Results for all experimental
groups are significantly increased over those of the corresponding control
group (P < 0.05 by the Mann-Whitney U test). Abbreviations are: C,
control group; H, hypercholesterolemic group.
Results less then 1.3 mmol/liter (the lowest detectable level) were
entered as 1.3 mmol/liter for statistical analysis
University of California, San Diego, CA, USA) [51]; rat al(I)
procollagen (supplied by Dr. S. Thorgeirsson, National Cancer
Institute, Bethesda, MD, USA); murine al(IH) procollagen (sup-
plied by Dr. Y. Yamada, National Institutes of Health, Bethesda,
MD, USA); murine a2(IV) procollagen (supplied by Dr. M.
Kurkinen, University of New Jersey, Rutgers Medical School,
Piscataway, NJ, USA); fibronectin (supplied by Dr. R. Hynes,
Center for Cancer Research, Massachusetts Institute of Technol-
ogy, Cambridge, MA, USA); mouse tenascin (supplied by Dr. P.
Ekblom, Uppsala University, Sweden); murine TIMP-1 (supplied
by Dr. R. Khokha, London Regional Cancer Centre, London,
ON, Canada); rat plasminogen-activator inhibitor-I (rat PAl-i;
supplied by Dr. Z.R. Gelehrter, University of Michigan, Ann
Arbor, MI, USA); and rat jsPA (supplied by Dr. J. Degan,
Children's Hospital Research Foundation, Cincinnati, OH, USA).
Unreferenced probes have been cited in earlier publications [42,
45, 47, 48].
Statistical analysis
Results for experimental animals at weeks 4, 8, and 12 were
compared with corresponding results for control animals using the
Mann-Whitney U-test. A P value under 0.05 was considered
statistically significant.
Results
Renal firnction
Excretion rates for urinary albumin among hypercholester-
olemic rats were significantly elevated at 4, 8, and 12 weeks; serum
creatinine levels were elevated at 12 weeks (Table 1).
Lipid abnormalities
Rats fed the high-cholesterol diet had significantly increased
serum cholesterol levels and renal peroxidation products at weeks
4, 8, and 12 (Table 2). Oil redO staining demonstrated significant
intraglomerular lipid deposits by week 4; these deposits continued
to enlarge at 8 and 12 weeks (Fig. IA). At weeks 4 and 8, a few
interstitial cells contained lipid deposits, while positive-staining
tubules were very infrequent. By 12 weeks, numerous oil red
0-positive cells were seen throughout the interstitium. The tu-
bules showed positivity, but to a lesser extent (Figs. 1 B, C).
Immunostaining using a monoclonal antibody to arachidonic
acid-modified lipoproteins showed an increase in tubular staining
and reactivity with tubular droplets of protein (Fig. 2A). Staining
in control kidney sections showed reactivity with vessel walls and
glomerular endothelial cells, and weak reactivity with some tu-
bules. Immunostaining using a monoclonal antibody to linoleic
Parameter
Body weight g
Urinary albumin mg/I00 g
body wt/day
Serum creatinine j.unol/liter
Interstitial macrophages per
1000 tubulointerstitial cells
Glomerular cells per
glomerular cross-section
Kidney weight mg
Table 2. Lipid abnormalities
-r, I '
C
0
a
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Fig. 1. Light photomicrograph of oil red 0 staining of the kidneys of rats
with diet-induced hypercholesterolemia. (A) Prominent glomerular deposits
are evident at four weeks and progressively increase over 12 weeks as
illustrated (X290). (B) At 12 weeks, neutral lipid deposits are present in
the intcrstitium and to a lesser extent in tubular cells (X270). (C) A rat
kidney from the control group does not contain oil red 0-positive neutral
lipid deposits (X330).
acid-modified lipoproteins demonstrated reactivity with discrete
interstitial cells and tubular protein droplets (Fig. 2B), whereas
sections of control kidneys showed negative results. Using vimen-
tin expression as a marker for regenerating tubules, tubular
damage did not appear to be a major feature of the tubulointer-
stitial disease associated with diet-induced hypercholesterolemia.
No vimentin-positive tubules were seen at 4 or 8 weeks; cortical
tubules only very rarely expressed vimentin reactivity at 12 weeks.
Renal expression of monocyte chemoattractants, adhesion
molecules, and a smooth-muscle actin
The number of interstitial macrophages was significantly in-
creased in the experimental groups in those killed at weeks 8 and
12 (Table 1). Renal MCP-1 mRNA levels were significantly
increased at week 8 (Table 3). Although not seen in control
kidneys, occasional MCP-1-positive cells were present within the
interstitium after 8 and 12 weeks of hypercholesterolemia. Renal
cortical osteopontin mRNA levels were significantly elevated in
all three groups of experimental animals (Table 3). Osteopontin
was not expressed in the immunostained renal cortex of normal
rats. Several cortical tubules expressed osteopontin, primarily
along the apical membrane, in rats on the high-cholesterol diet.
VCAM-1 mRNA levels were significantly elevated in rats of the
high-cholesterol group examined at 12 weeks (Table 3). In normal
rats, VCAM-1 protein was found in perituhular interstitial cells; in
the high-cholesterol group there was an increase in the number of
VCAM-1-positive interstitial cells at 4, 8, and 12 weeks (Fig. 3 A,
B). In kidneys from control rats, cortical arterioles showed strong
a smooth-muscle actin staining (Fig. 3D). Occasional foci of cells
positive for a smooth-muscle actin were present in the intersti-
tium after 12 weeks of hypercholesterolemia (Fig. 3C).
Renal cytokine and growth factor expression
Renal TGF-pl mRNA levels were significantly increased at 4
and 12 weeks (Fig. 4). In control animals TGF-/31 immunostaining
revealed positive cells in vessel walls and glomeruli and occasional
positive tubules. At 4 and 8 weeks there was an increase in the
number of TGF-[31 positive intraglomerular cells and positive
tubules. At 12 weeks foci of positive interstitial cells were also
present (Fig. 5). Renal cortical M-CSF mRNA levels were
significantly elevated in the hypercholesterolemic rats at 4 weeks
(1.4 0.2 vs. 1.0 0.3 arbitrary units) and IL-lp mRNA levels
were significantly elevated in the hypercholesterolemic rats at 12
weeks (2.9 1.6 vs. 1.0 0.3 arbitrary units). Renal mRNA levels
were not significantly increased for TNF-a or for PDGF-A at 4, 8,
or 12 weeks in the hypercholesterolemic rat groups. In fact renal
mRNA levels were significantly decreased at four weeks for TNFa
(0.5 0.3 vs. 1.0 0.4 arbitrary units, respectively) and for MCSF
at 12 weeks (0.6 0.4 vs. 1.0 0.3 arbitrary units).
Renal interstitial matrix proteins
The total kidney collagen content was significantly increased
after 12 weeks of hypercholesterolemia (9.8 0.9 mg/kidney vs.
Parameter Group Week 4 Week 8 Week 12
MCP-1 C
H
1.0 0.4
0.7 0.2
1.0 0.2
2.2 1.la
1.0 0.8
2.4 1.9
Osteopontin C
H
1.0 0.4
2.9 0.4
1.0 0.6
2.4 0.8
1.0 0.7
2.1 0.7a
VCAM-1 C
H
1.0 0.4
1.1 0.4
1.0 0.6
1.0 0.5
1.0 0.4
2.! 0.5
Results are means I so (N = 7/group), expressed in arbitrary
densitometric units. Abbreviations are: C, control group; H, hypercholes-
terolemic group; MCP-1, monocyte chemoattractant protein-i; VCAM-l,
vascular cell adhesion molecule-i.
P < 0.05 compared to the corresponding control group, by the
Mann-Whitney U test
Fig. 2. Immunostainingfbr oxidalively modified lipoproteins in hypercholes-
terolemic rats. (A) Arachidonic acid-modified lipoproteins within tubular
cells and droplets (X290). (B) Linoleic acid-modified lipoprotcins within
interstitial cells (x250).
7.8 0.9 mg in controls; Fig. 6). At this time, a significant number
of interstitial fields had increased immunostaining for collagen I,
collagen III, collagen IV, fibronectin and tenascin (19 27%,
11 13%, 9 11%, 26 26% and 16 21% of interstitial fields,
respectively, showed increased interstitial immunostairling com-
pared to control animals; Fig. 7). Interstitial immunostaining for
collagen Ill did not show a statistically significant difference at 4
or 8 weeks in the hypercholesterolemic rats (0 0% and 2 3%
of interstitial fields with increased immunostaining, respectively).
Renal matrix protein mRNA levels at weeks 4, 8, and 12 are
summarized in Table 4. The only statistically significant elevations
were in procollagen ai(I) at 12 weeks and procollagen ai(III)
levels at 8 and 12 weeks (Fig. 8).
Renal protease/protease inhibitor mRNA levels
Renal TIMP-1 mRNA levels were significantly elevated at 4, 8
and 12 weeks in the hypercholesterolemic rats (Table 5 and Fig.
9). By immunostaining, TIMP-1 protein appeared de novo in the
interstitium of the hypercholesterolemic rats, beginning at four
weeks (Fig. bA). Renal PAl-i mRNA levels were increased at
four weeks, but were similar in control and experimental groups at
8 and 12 weeks. Renal j.tPA mRNA levels were significantly
decreased in all experimental groups (Table 5 and Fig. 11).
Oxidized low-density lipoproteins play a pivotal role in the
pathogenesis of atherosclerosis [23]. Several lines of evidence also
suggest that lipoproteins are among the list of factors that cause
glomeruloscierosis, perhaps by mimicking some of the atheroscle-
rotic mechanistic pathways [5, 6, 14, 15, 52—561. The results of the
present study in uninephrectomized rats with diet-induced hyper-
cholesterolemia suggest that lipoproteins may also contribute to
the interstitial inflammation and fibrosis that typifies chronic
progressive renal disease. In this model, glomerular changes occur
early, while convincing tubulointerstitial pathology is delayed until
after eight weeks of hypercholesterolemia.
Interstitial macrophages and renal tubular cells are able to
internalize lipoproteins in vitro [31, 571. After four weeks of
hypercholesterolemia and prior to the onset of interstitial inflam-
mation, oil red 0 staining identified lipid deposits within a few
interstitial cells. By 12 weeks, numerous oil red 0-positive inter-
stitial cells were seen, likely within both resident and infiltrating
interstitial macrophages. Not evident at four weeks, by 12 weeks
lipid deposits were also detected in many tubules. Additional
evidence suggests that a proportion of these tubulointerstitial lipid
deposits are oxidized lipoproteins. Based on measurement of
renal malondialydehyde levels, renal lipid peroxidation products
were significantly increased. Immunostaining using monoclonal
antibodies that recognize oxidation-specific epitopes characteris-
tic of oxidized LDL confirmed the intracellular uptake of arachi-
donic acid-modified lipoproteins by tubular cells and linoleic
acid-modified lipoproteins by interstitial cells. In addition, both of
these antibodies reacted with tubular protein droplets.
Oxidized LDL is taken up by scavenger receptors but not by
native LDL receptors. The molecular basis of in vivo LDL
oxidation remains unclear, although the release of reactive oxygen
metabolites by perivascular cells and interstitial macrophages
likely plays a role [311. It is possible that oxidation occurs mainly
in the extravascular interstitial space, where the balance between
endogenous oxidants and antioxidants favors oxidation [71. After
oxidation, LDL has an affinity for type I collagen [58] that may
lead to entrapment in the interstitial microenvironment. Macro-
phages are an important source of scavenger receptors; studies
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Table 3. Renal adhesion and chemoattractant molecule mRNA levels
Several cortical tubules reacted with the anti-human 1xPA anti-
serum; however, no significant difference in the intensity of the
staining could be discerned by immunofluorescence microscopy
(Fig. lOB).
Discussion
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Fig. 3. Immunofluorescence photomicrographs illustrating (A) increased numbers of interstitial cells expressing VC4M-1 (X 240) compared to (B) control
animals (x270), and (C) foci of interstitial cells expressing a smooth-muscle actin in the kidneys of hypercholesterolemic rats (X300). (D) In control rats,
a smooth-muscle actin is only found in the walls of arterioles (x310).
have not yet been done to confirm the expression of these
receptors on renal tubular cells.
In the present study, tubular expression of the intermediate
filament vimentin was used as a marker for recent tubular injury.
The results of this study suggest that tubular uptake of lipopro-
teins does not cause significant tubular damage in vivo. This
finding contrasts with in vitro studies documenting that significant
tubular injury can be induced by oxLDL [31, 32]. This observation
led us to speculate that the accumulation of oxidized lipoproteins
within tubular and interstitial cells might trigger intrarenal prom-
flammatory and profibrogenic events. Scavenger receptors may
activate numerous cellular pathways. In vitro studies have re-
ported increased production of granulocyte and macrophage
colony-stimulating factors, basic fibroblast growth factor [59], and
platelet-derived growth factor 1601 by endothelial cells exposed to
oxLDL.
In this study we attempted to determine whether hypercholes-
terolemia altered the renal cortical expression of cytokines that
have been implicated in fibrogenesis. At the mRNA level,
TGF-/31 expression was hiphasic, with significantly increased
levels at 4 and 12 weeks. By 12 weeks, several TGF-1-positive
cells were present in the glomeruli and the interstitium, and the
Fig. 4. TGF-pl. (A) Northern blot of renal cortical RNA from individual
control rats and rats after 12 weeks of hypercholesterolemia. (B) The
results of the TGF-1 densitometric analysis, expressed in arbitrary units
and shown as means 1 so. Symbols are: () control; (•) high
cholesterol; * < 0.05, Mann-Whitney U-test.
TGF-Ø1
lBs
B
5.0
CD 4.0
3.0
Controls High cholesterol
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Fig. 5. TGF-pI immunofluorescence photomicrographs. (A) In normal
rats, TGF-1-positive cells are present within vessel walls (X340). (B)
After 12 wccks of diet-induced hypercholesterolemia, TGF-I3 I-positive
cells appear within glomeruli and the interstitium (arrows) (X350).
intensity of tubular staining was increased. Compared to those in
control kidneys, mRNA levels in the kidneys from rats with
hypercholesterolemia were significantly increased for M-CSF at 4
weeks and IL-lp at 12 weeks. Effects of oxLDL on TGF-J31
expression have not been extensively studied. Ding and Diamond
[61] have reported enhanced expression of TGF-pl by cultured
human glomerular epithelial cells in the presence of oxLDL.
Native LDL augmented TGF-f31 hioactivity in supernatants of
cultured rat mesangial cells [62].
Interstitial macrophages were significantly increased in the
hypercholesterolemic group. Based on the results of immuno-
staining, interstitial macrophages appear to be an important
source of TGF-131 production. Although the molecular basis of
interstitial monocyte recruitment in this model remains unclear,
MCP-1, VCAM-1, and osteopontin appear to be candidates.
Renal MCP-1 mRNA levels were significantly increased at 8
weeks. However, de novo renal expression of MCP-1 protein was
not observed via immunostaining. Only the occasional MCP-1-
positive interstitial cell was identified in the hypercholesterolemic
rats. VCAM-i mRNA levels were significantly increased at 12
weeks in the hypercholesterolemic rats. Again, immunostaining
suggested that this was due to an influx of VCAM-1-expressing
interstitial inflammatory cells rather than an increase in VCAM-1
E
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>'
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expression by intrinsic renal cells. It is possible that oxidized
lipoproteins up-regulated VCAM-1 expression on the interstitial
macrophages [27, 281, although we observed a similar population
of VCAM-1-positive interstitial cells in rats with protein-overload
proteinuria [47] in the absence of hypercholesterolemia [63].
Osteopontin is a glycoprotein with monocyte chemotactic activity
[64]. De novo expression of osteopontin by renal cortical tubules
co-localizes with interstitial monocyte accumulation in several
experimental models of renal disease [47, 65—67].
The appearance of interstitial myofibroblasts identified by their
expression of a smooth-muscle actin is characteristic of renal
diseases with progressive interstitial fibrosis. The origin and
specific function of these myofibroblasts remains unclear. They
may derive from resident interstitial fibroblasts, or they may be
perivascular cells. It is interesting that the interstitial disease that
developed in rats with hypercholesterolemia was characterized by
the appearance of relatively few interstitial myofibroblasts, com-
pared to other tubulointerstitial diseases such as obstructive
uropathy [681. It is likely that the 12-week timepoint represented
the initiation of myofibroblast transformation/migration and that
these cells may continue to increase with more advanced intersti-
tial fibrosis. However, it is worth noting that during the first 12
weeks of hypercholesterolemia, renal mRNA levels for genes
encoding matrix proteins were normal or only modestly increased
(see below), suggesting a link between myofibroblast transforma-
tion and up-regulated expression of matrix-encoding genes.
By 12 weeks, hypercholesterolemic rats developed significant
renal interstitial fibrosis, associated with a small but significant
elevation in the mean serum creatinine level. Semiquantitative
immunostaining confirmed a significant increase in collagen I,
collagen III, collagen IV, EDA fibronectin and tenascin. The
molecular basis of renal interstitial fibrosis in hypercholester-
olemic rats is not yet clear, although the results of this study
suggest some possibilities. Studies in several other animal models
of renal interstitial fibrosis [42, 45, 47, 48, 69—74] have suggested
that both increased matrix-protein synthesis and decreased matrix
turnover participate. What is particularly intriguing in the present
study is that renal matrix protein mRNA levels did not show a
striking difference between control and experimental animals. The
elevations in procollagen al(I) and procollagen al(III) mRNA
levels at 12 weeks were only 30% and 70% above control levels,
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Fig. 6. Total kidney collagen in hypercholesterolemic rats. Results are
means I so. Symbols are: () controls; (•) high cholesterol; *P < 0.05,
Mann-Whitney U-test.
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Fig. 7. Immunofluorescence photomicroaphs illustrating the renal interstitial accumulation of matrix proteins in hypercholesterolemic rats. (A) control
EDA fibronectin; (B) 12-week experimental EDA fibronectin; (C) control collagen I; and (D) 12-week experimental collagen I (all X310).
Table 4. Renal matrix protein mRNA levels
Group Week 4
Procollagen csl(1) C 1.0 0.2 1.0 0.2 1.0 0.1
H 0.9 0.1 1.0 0.3 1.3 0.3
Procollagen al(III) C 1.0 0.2 1.0 0.3 1.0 0.2
H 1.2 0.2 1.4 0.2" 1.7 0.3'
Procollagen uI(IV) C 1.0 0.1 1.0 0.1 1.0 0.3
H 1.2 0.4 0.6 0.1" 1.0 0.2
Fibronectin C 1.0 0.5 1.0 0.4 1.0 0.4
H 1.0 0.4 0.6 0.2" 1.1 0.2
Tenascin C 1.0 0.5 1.0 0.3 1.0 0.3
H 0.9 0.4 1.7 0.9 0.7 0.3
Results are means 1 SI) (N = 7/group), expressed in arbitrary
densitometric units. Abbreviations are: C, control group; H, hypercholes-
tcrolemic group.
"P < t).05 compared to the corresponding control group, by the
Mann-Whitney U test.
respectively. Although we did not measure actual matrix protein
synthesis rates in this study, transcriptional regulation of matrix-
encoding genes is an important and often rate-limiting step. A
recent study by Tamaki ct al [75] showed a good correlation
between renal fibronectin mRNA levels and rates of fibronectin
synthesis in rats with adriamycin-induced nephrosis.
The modest changes in renal matrix protein mRNA levels
suggested the possibility that decreased rates of matrix turnover
Fig. 8. Northern blot of renal cortical procollagen aJ(III) mRN.4 levels in
uninephrectomized control rats and rats after 12 weeks of diet-induced
hypercholesterolemia. The mean densitometric scores expressed in arbi-
trary units were 1.0 0.2 for the control group and 1.7 0.3 for the
hypercholesterolemic group.
played a role in the pathogenesis of interstitial fibrosis in the
hypercholesterolemic rats. Two proteolytic cascades are thought
to participate in degradation of renal interstitial matrix proteins:
the metalloproteinases and the serine proteases. The metallopro-
teinase family is a large family consisting of three enzyme groups
and three enzyme inhibitors. TIMP-1 is a glycoprotein that is
elaborated by virtually all mesenchymal tissues, including intrinsic
glomerular cells, inflammatory cells such as macrophages, and
fibrohlasts [76]. TIMP-1 inhibits all active as well as many latent
matrix metalloproteinascs.
TIMP-1 mRNA levels were significantly increased in the hyper-
cholesterolemic rats at 4, 8 and 12 weeks. TIMP-1 mRNA levels
are elevated in several experimental models of renal fibrosis,
Parameter Week 8 Week 12
___—
-r
Controls High cholesterol I
TIMP-1
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Parameter
TTMP-1
Group Week 4 Week 8 Week 12
C 1.0 0.4 1.0 0.5 1.0 0.4
H 1.4 0.5a 2.7 0.9a 2.7 1.4
PAl-i C
H
1.0 0.4
1.3 0.3a
1.0 0.3
0.9 0.3
1.0 0.5
1.1 0.3
1sPA C
H
1.0 0.4
0.4 o.ia
1.0 0.3
0.4 0.1
1.0 0.4
0.4 0.1
Results are means 1 SD (N = 7/group), expressed in arbitrary
densitometric units. Abbreviations are: C, eontrol group; H, hypereholes-
terolemic group; /LPA, urokinase-type plasminogen activator; PAT-i,
plasminogen-activator inhibitor-i; TIMP-1, tissue inhibitor of metallopro-
teinases-1.
P < 0.05 compared to the corresponding control group, by the
Mann-Whitney U test
Fig. 9. Northern blot of renal cortical TIMP-1 mRNA levels for uninephrec-
tomized control rats and rats fed a high-cholesterol diet/br eight weeks. The
mean densitometric scores were 1.0 0.4 arbitrary units for the control
group and 2.7 0.9 units for the hypercholesterolemic group.
including puromycin aminonucleoside nephrosis [42, 45, 48],
protein-overload proteinuria [471, passive Fleymann nephritis
[771, anti-tubular basement membrane nephritis [71], obstructive
uropathy [69, 70], and diabetic nephropathy [781. Absent in
control kidney sections, TIMP-1 protein appeared de novo as a
extracellular interstitial protein in rats with hypercholesterolemia,
a pattern that has been observed in other animal models. Prelim-
inary in situ hybridization studies (A.A. Eddy, unpublished obser-
vations) in rats with puromycin aminonucleoside nephrosis have
indicated that both tubular and interstitial cells are the site of
increased TIMP-1 expression during interstitial fibrosis. We have
never found increased renal mRNA levels for matrix protein-
degrading metalloproteinases in any of the models of renal
interstitial fibrosis that we have studied. These results predict a
reduction in metalloproteinase activity in the kidneys of hyper-
cholesterolemic rats.
The second important pathway that has been implicated in
renal matrix remodeling is the plasmin-dependent pathway. Per-
haps most important is the ability of plasmin to activate latent
procollagenases, although plasmin itself may degrade certain
matrix proteins such as fibronectin. Biologically active plasmin is
released from latent plasminogen by the proteolytic activity of the
plasminogen activators. Within the kidney, urokinase-type plas-
minogen activator (xPA) is thought to be the most abundant
enzyme and is produced by proximal, distal, and collecting tubules
[79, 80]. In rats with hypercholesterolemia, renal xPA mRNA
levels were significantly reduced at 4, 8, and 12 weeks, compared
to control kidneys. The activity of xPA is inhibited by plasmino-
gen activator inhibitor-i. In the hypercholesterolemic rats, renal
PAL-i mRNA levels were transiently increased at four weeks but
were similar to control rats at 8 and 12 weeks. These results
suggest that the intrarenal activity of the plasmin-dependent
pathway is also depressed in hypercholesterolemic rats.
Fig. 10. Immunofluorescence photomicrographs illustrating: (A) the de
nova expression of TIMP-1 within the interstitium of rats after 12 weeks of
hypercholesterolemia (x280); and (B) the tubular expression of p.PA, a
pattern that was similar in control and hypercholesterolemic rats (X280).
Fig. 11. Renal cortical p.PA mRNA levels for uninephrectomized control rats
and rats fed a high-cholesterol diet Jbr 12 weeks. The mean densitometric
scores were 1.0 0.4 arbitrary units for the control group and 0.4 0.1
units for the hypercholesterolemic group.
In summary, uninephrectomized rats fed a high cholesterol diet
develop hypercholesterolemia and progressive renal disease. The
renal interstitial disease develops slowly over several weeks.
Following the accumulation of lipids within tubulointcrstitial cells,
interstitial nephritis develops, characterized by an infiltrate of
macrophages and the appearance of occasional myofibroblasts.
Interstitial fibrosis and renal functional impairment are estab-
lished by 12 weeks. The fibrosis is characterized by increased
intrarenal expression of TGF-J31 and TIMP-1 and decreased
expression of xPA. We speculate that oxidized LDL-mediated
Table 5. Renal protease and protease-inhibitor mRNA levels
Contro4s High cholesterol
uPA
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scavenger receptor activation plays a role in the fibrogenic cas-
cade, a hypothesis that is currently under investigation using
antioxidant drugs.
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Appendix
Abbreviations are: jrPA, urokinase-type plasminogen activator; EDA,
extracellular domain A; ICAM-1, intercellular adhesion molecule-I; IL-
113, interlcukin-1 beta; LDL, low-density lipoprotein; MCP-l, monocyte
chemoattractant protein-I; M-CSF, macrophage colony-stimulating fac-
tor; oxLDL, oxidized low-density lipoprotein; PAl-I, plasminogen-activa-
tor inhibitor-I; PDGF, platelet-derived growth factor; TGF-f31, transform-
ing growth factor beta-i; TIMP- 1, tissue inhibitor of metalloprotcinases- 1;
TNF-cs, tumor-necrosis factor alpha; 1sPA, urokinase-type plasminogen
activator; VCAM-I, vascular cell adhesion molecule-i.
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